![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 29, 20465-20472, July 16, 1999
§,
**
,
,
,
From the Departments of Erythropoietin (Epo) activates a
voltage-independent Ca2+ channel that is dependent on
tyrosine phosphorylation. To identify the domain(s) of the Epo receptor
(Epo-R) required for Epo-induced Ca2+ influx, Chinese
hamster ovary (CHO) cells were transfected with wild-type or mutant Epo
receptors subcloned into pTracer-cytomegalovirus vector. This vector
contains an SV40 early promoter, which drives expression of the green
fluorescent protein (GFP) gene, and a cytomegalovirus immediate-early
promoter driving expression of the Epo-R. Successful transfection was
verified in single cells by detection of GFP, and intracellular
Ca2+ ([Ca]i) changes were simultaneously
monitored with rhod-2. Transfection of CHO cells with pTracer encoding
wild-type Epo-R, but not pTracer alone, resulted in an Epo-induced
[Ca]i increase that was abolished in cells transfected with
Epo-R F8 (all eight cytoplasmic tyrosines substituted). Transfection
with carboxyl-terminal deletion mutants indicated that removal of the terminal four tyrosine phosphorylation sites, but not the tyrosine at
position 479, abolished Epo-induced [Ca]i increase, suggesting that tyrosines at positions 443, 460, and/or 464 are important. In CHO cells transfected with mutant Epo-R in which phenylalanine was substituted for individual tyrosines, a significant increase in [Ca]i was observed with mutants Epo-R Y443F and
Epo-R Y464F. The rise in [Ca]i was abolished in cells transfected with Epo-R Y460F. Results were confirmed with CHO cells
transfected with plasmids expressing Epo-R mutants in which individual
tyrosines were added back to Epo-R F8 and in stably transfected Ba/F3
cells. These results demonstrate a critical role for the Epo-R
cytoplasmic tyrosine 460 in Epo-stimulated Ca2+ influx.
Erythropoietin is a hematopoietic growth factor that regulates the
proliferation, differentiation, and viability of erythroid progenitors
and precursors (1). The erythropoietin receptor is a member of the
superfamily of cytokine receptors (2, 3), which is characterized by the
conservation of cysteines and a WSXWS motif in the extracellular domain
(1-8), as well as limited similarities in the cytoplasmic domain,
including Box 1 and Box 2 in the membrane proximal region (2, 3). No
kinase or other enzyme motif has been identified in the cytoplasmic
domains of members of the cytokine receptor superfamily. For
erythropoietin, interaction with its receptor rapidly induces
dimerization/oligomerization (9, 10), which results in increased
affinity for a member of the Janus family of cytoplasmic tyrosine
kinases, JAK2 (9-12). JAK2 is activated by transphosphorylation of its
active site and phosphorylates some or all of the eight tyrosine
residues in the intracellular domain of the
Epo1 receptor. JAK2 also is
activated by other cytokine receptors, including thrombopoietin,
prolactin, and growth hormone (2, 3, 13). Phosphorylation of the
intracellular tyrosines attracts other intracellular proteins that bind
to Epo-R via their Src homology 2 (SH2) domains; many are in turn
tyrosinephosphorylated (14).
Identification of the phosphorylated tyrosines of the erythropoietin
receptor to which specific SH2-containing proteins bind is important in
defining the pathways involved in erythropoietin stimulated
proliferation and differentiation. Tyrosine at position 343 or 401 of
the murine Epo-R mediates maximal STAT5 activation (15-20). The
proliferation stimulating SH2-containing tyrosine phosphatase SHP2 is
phosphorylated by JAK2 after binding at position 401 (21, 22). The
proliferation inhibiting SH2-containing tyrosine phosphatase SHP1 is
recruited to the Epo receptor following the phosphorylation of tyrosine
429, resulting in inactivation of JAK2 and termination of proliferative
signals (23, 24). Phosphatidylinositol 3-kinase directly associates
with the murine erythropoietin receptor at amino acids 479 and 343 (25-27). Other kinases/signal transducers that are
tyrosine-phosphorylated in response to erythropoietin include GAP (28),
Shc (14), Vav (29), c-fps/fes (30), Lyn (31), phospholipase C- Ligand binding of the Epo-R causes an increase in intracellular
Ca2+, and it is believed that this is part of the signaling
mechanisms controlling proliferation/differentiation of human (35-37)
and murine (38-42) erythroid progenitors and precursors. The mechanism of regulation of calcium by erythropoietin has been examined at the
single cell level using normal human burst-forming
units-erythroid-derived cells at defined stages of differentiation and
fluorescence microscopy coupled to digital video imaging (35, 36, 43,
44), patch clamp (44, 45), and microinjection (46). Our laboratory has
shown that erythropoietin induces a dose-dependent increase in [Ca]i in single normal human BFU-E-derived erythroblasts modulated through a voltage-independent ion channel permeable to
calcium (44, 45) and dependent on tyrosine phosphorylation (47). Here,
we identified the domain of the Epo receptor required for Epo-induced
calcium influx using a system in which single cells that expressed
transfected wild-type or mutant erythropoietin receptors were
identified by detection of green fluorescent protein (GFP) with digital
video imaging and cytosolic Ca2+ changes simultaneously
measured in transfected cells.
Transfection of Wild-type and Mutant Epo Receptors into CHO
Cells--
CHO cells were cultured in DMEM with 10% fetal calf serum
at 37 °C in 5% CO2. All constructs were based on the
pTracer-CMV vector (Invitrogen). This mammalian expression vector
contains an SV40 early promoter that drives expression of the GFP gene fused to a zeocin resistance gene and a CMV immediate-early promoter driving expression of a second cDNA.
A panel of Epo-R deletion mutants (see Fig. 2) was generated as
described previously (48). Briefly, a region from nucleotide 1083 to
the specific 3'-end of each construct was amplified via polymerase
chain reaction. After subcloning the polymerase chain reaction fragment
into pCR-Script, the fragment was digested with SphI and
EcoRI and subcloned into
SphI-EcoRI-digested pCDNA3-EPO-R. The Epo-R
CHO cells were transfected with transfection solution containing
pTracer-CMV vectors (6 µg/ml) and LipofectAMINETM (Life Technologies, Inc.; 16 µg/ml) for 5 h at 37 °C. Successful transfection of
CHO cells was verified by detection of expression of green fluorescent protein by digital video imaging (44-46). The excitation peaks of GFP
are 395 and 478 nm, and the emission peak is 507 nm. Cells were excited
at 380 nm, and emission was detected at 510 nm. The optimal time for
expression of transfected pTracer CMV Epo-R was found to be 48-72 h
after transfection by Western blotting, and this time interval
posttransfection was selected to examine the response of transfected
CHO cells to Epo. At this time interval, 40-50% of CHO cells
expressed GFP.
Measurement of [Ca]i with Digital Video Imaging--
A
fluorescence microscopy coupled digital video imaging system was used
to measure [Ca]i (35, 36, 43-46). To study changes in
intracellular calcium in transfected cells, we were not able to use
Fura-2 as the detection fluorophore because its excitation and emission
wavelengths overlap with those of GFP. Instead, we used the
fluorescence indicator rhod-2 (Molecular Probes, Eugene, OR) (49, 50).
Fluorescence of GFP does not interfere with rhod-2 fluorescence. Rhod-2
is a single wavelength excitation Ca2+ fluorophore
(excitation, 540 nm; emission, 590 nm). We cannot obtain absolute
[Ca]i values in single cells, because fluorescence is
proportional to [Ca]i, fluorophore concentration, optical
path, and excitation light intensity. Fo (fluorescence at baseline) and
Ft (fluorescence at time t) were measured and used to
quantitate changes in [Ca]i in rhod-2 loaded CHO cells. Using
the peak Ft measurement 20 min after Epo stimulation, Ft/Fo × 100% was calculated and used for standardization to compare changes
between groups. CHO cells were loaded by incubation with rhod-2 (2 µM) for 30 min at 37 °C and stimulated with
recombinant erythropoietin (>100,000 units/mg; R & D Systems, Inc.,
Minneapolis, MN). Baseline measurements of Fo were taken before
stimulation, and measurements of Ft were taken at 1, 5, 10, 15, and 20 min after Epo stimulation. Experiments were performed with or without physiological calcium (0.7 mM) (36). Pertussis toxin was
obtained from List Biological Laboratory (Campbell, CA) and was
heat-inactivated by incubating at 95 °C for 20 min (51).
Immunoblotting--
Whole cell lysates were prepared, and ECL
was performed as described previously (52). Membranes were incubated
with anti-mEpo-R antibody (sc-697, Santa Cruz Biotechnology, Santa
Cruz, CA; diluted 1:100). Donkey anti-rabbit antibody (1:1500) was used
as the secondary antibody.
To analyze Epo-dependent JAK2 tyrosine phosphorylation in
stably transfected Ba/F3 cells, we used a JAK2 polyclonal antibody for
immunoprecipitations (53) and a different JAK2 polyclonal antibody
(Upstate Biotechnology, Inc., Lake Placid, NY) for Western analysis.
The monoclonal anti-phosphotyrosine 4G10 antibody was generously
provided by Dr. Brian Druker (Portland, OR).
Measurement of [Ca]i and Cell Proliferation in
Transfected Ba/F3 Cells--
To confirm our results in a
factor-dependent hematopoietic cell line, we studied Ba/F3
cells stably transfected with wild-type or mutant mEpo-R (34). Ba/F3
cells transfected with wt or mutant mEpo-R were cultured with 1 mg/ml
G418 (Life Technologies, Inc., Gaithersburg, MD) and 500 pg/ml IL-3.
Ba/F3 and Ba/F3 mEpo-R cells were adhered to fibronectin coated
coverslips, growth factor deprived for 5 h, and loaded with 2 µM Fura-2 acetoxymethyl ester (Molecular Probes, Inc.)
for digital video imaging studies (35, 36, 46, 47).
Transfection of CHO Cells with pTracer-CMV Epo-R--
To determine
the domains of the Epo-R required for erythropoietin regulation of
calcium channels, we established a system in which single cells
transfected with wild-type or mutant Epo-R could be identified by GFP
fluorescence, and [Ca]i was measured simultaneously in the
identical cells with digital video imaging. CHO cells were used for
these transfections, because they lack endogenous Epo-R and have been
shown to contain all the necessary transducers required for growth
hormone-induced [Ca]i increase (54). In Fig.
1, five CHO cells are shown 24 h
after transfection with Epo-R subcloned into the pTracer-CMV vector.
Successfully transfected CHO cells were detected by fluorescence from
GFP (Fig. 1B). [Ca]i detected by intracellular
rhod-2 is shown for the same five cells in Fig. 1C. A
significant increase in [Ca]i was observed in CHO cells
stimulated with Epo following transfection with pTracer-CMV mEpo-R
(Table I, p < 0.02). The
rate of rise in intracellular calcium was similar to that previously
observed in BFU-E-derived cells (35, 36). The magnitude of
[Ca]i changes cannot be directly compared because we were
unable to calibrate rhod-2 signals into [Ca]i, and rhod-2 was
observed to have a smaller dynamic range than Fura-2. No change in Ft
measured at 10-s intervals compared with Fo was observed over the first
minute (data not shown). No increase in [Ca]i was observed in
Epo treated CHO cells transfected with vector alone. Nontransfected CHO
cells (e.g. the other four cells in Fig. 1C) did
not demonstrate a significant change in percentage of Ft/Fo over the
experimental period (20 min), indicating that problems due to leakage
and photobleaching of rhod-2 are minimal (no decrease in Ft/Fo), and
that the increase in [Ca]i in successfully transfected CHO
cells was specific for Epo.
The Ca2+ response to erythropoietin was then further
characterized in CHO cells. The rise in intracellular Ca2+
was dependent on extracellular calcium, because no response to erythropoietin was seen in medium without calcium (data not shown). Pretreatment with pertussis toxin, but not heat-inactivated pertussis toxin, significantly inhibited the increase in percentage of Ft/Fo observed in Epo-stimulated pTracer-CMV mEpo-R transfected CHO cells
(Table I, p < 0.002). These results demonstrated that
the influx of calcium in CHO cells is regulated by a pertussis
toxin-sensitive G protein. CHO cells transfected with pTracer-CMV
mEpo-R were then pretreated with the L-type
Ca2+ channel blocker nifedipine. Nifedipine blocked the
increase in [Ca]i seen in response to erythropoietin, but
only at doses higher than typically required to block voltage-sensitive L-type calcium channels (Table
II). These data confirm that the Epo-R in
transfected CHO cells behaved similarly to the endogenous Epo-R on
BFU-E-derived cells (44-46, 51).
Identification of Erythropoietin Receptor Domains Involved in
Calcium Channel Activation Using Receptor Deletion Mutants--
To
determine erythropoietin receptor domains required for Epo-induced
calcium influx, CHO cells were transfected with wild-type or mutant Epo
receptors subcloned into pTracer-CMV vector. We initially selected a
mutant receptor in which phenylalanine was substituted for all eight
tyrosines (F8), because tyrosine phosphorylation is required for the
Epo-modulated calcium increase (47). Transfection with the Epo-R F8
mutant abolished the Epo-induced intracellular calcium increase (Table
III). CHO cells were then transfected
with carboxyl-terminal deletion mutants to narrow the number of
tyrosine sites that might be involved (Fig.
2). CHO cells transfected with the mEpo-R
carboxyl-terminal deletion mutants Identification of the Tyrosine(s) Involved in Epo-Receptor Mediated
Calcium Influx--
CHO cells were then transfected with mutant mEpo-R
in which phenylalanine was substituted for individual tyrosines at
positions 443, 460, or 464 (Fig. 3). In
cells transfected with mEpo-R Y443F and mEpo-R Y464F, the significant
increase in [Ca]i in response to Epo stimulation was similar
to that observed with the wild-type mEpo-R (Table
IV). In contrast, the increase in percentage of Ft/Fo was abolished in cells transfected with mEpo-R Y460F.
To confirm that a single tyrosine residue was sufficient to mediate
Epo-R modulated Ca2+ influx, CHO cells were transfected
with pTracer expressing mutants in which single tyrosines were added
back to a mEpo-R devoid of tyrosine residues (Epo-R F8). A significant
increase in [Ca]i in response to Epo was observed in cells
transfected with mEpo-R F7 Tyr-460 but not in cells transfected with
mEpo-R F7 Tyr-443 or F7 Tyr-464 (Table IV). These results demonstrate
that the Epo-R cytoplasmic tyrosine at position 460 is necessary and
sufficient for Epo-stimulated Ca2+ influx.
Western blotting was performed on lysates of transfected CHO cells and
demonstrated that all tyrosine substitution and add back mutants were
expressed (Fig. 4A). As
observed for wt mEpo-R, receptor expression was greater at 48 than
72 h after transfection. The deletion mutant mEpo-R-14, shown here
as a negative control, was not recognized by this antibody, which was
raised against the carboxyl-terminal 20 amino acids.
Role of mEpo-R Tyr-460 in Hematopoietic Cells--
To confirm
these findings in hematopoietic cells, the ability of erythropoietin to
modulate [Ca]i in Ba/F3 cells stably transfected with
wild-type or mutant mEpo-R was examined. Subclones were isolated via
limiting dilution and individual subclones were selected that expressed
comparable levels of Epo-R expression (Fig. 4B). Stable
transfection of mEpo-R was maintained by antibiotic selection, and the
level of receptor expression in a single cell could not be assessed.
A significant increase in F350/F380 was
observed folflowing Epo stimulation in Ba/F3 cells transfected with
mEpo-R, but not in parental cells (Fig.
5). No increase in
F350/F380 was found when measurements were
obtained at 10 s intervals for the first minute. Cells transfected
with the mEpo-R deletion mutant We have transfected CHO cells with wild-type and mutant mEpo
receptors to study the erythropoietin signal transduction pathway involved in calcium channel activation. Digital video imaging was used
to identify GFP fluorescence in single cells transfected with the
pTracer vector, which expresses both the GFP and Epo receptor genes.
The pTracer vector possesses the theoretical advantage that the gene of
interest is not expressed as a fusion protein with GFP, which may
affect targeting of the protein under study or modify its function or
regulation. Calcium channel activation in response to erythropoietin
was measured in transfected cells loaded with rhod-2. We are the first
to study receptor-mediated calcium signaling in which successful
transfection with the gene of interest was authenticated at the single
cell level by fluorescence emissions from GFP, a co-transfected gene.
Our method can be applied to many receptor/channel systems.
We previously demonstrated that erythropoietin modulates a
voltage-independent calcium channel on normal erythroid precursors (35-36, 44-45) that is dependent on tyrosine kinase activation (47). The results reported here, demonstrating the importance of the tyrosine
at position 460 in calcium channel activation, are consistent with our
previous data. Signal transducers that interact with Tyr-460 and the
subsequent signaling pathway(s) involved have not yet been identified.
One potential transducer, Ras, has been shown to couple to calcium
channel entry in other systems. Insulin-like growth factors I and II
have been shown to activate a calcium-permeable channel by a mechanism
involving a pertussis toxin-sensitive GTP-binding protein, Gi Erythropoietin has previously been shown to induce tyrosine
phosphorylation and activation of phospholipase C- Recent studies suggest that phosphatidylinositol 3,4,5-trisphosphate is
an activator of calcium channel activity in mast cells (59, 60). The
SH2 inositol 5' phosphatase SHIP has been shown to abrogate
receptor-induced phosphatidylinositol 3,4,5-trisphosphate accumulation
regulated by PLC- Two other members of the cytokine superfamily, growth hormone (54) and
prolactin (62), mediate a slow increase in intracellular free calcium.
The Ca2+ response to growth hormone, like that of Epo, is
dependent on external calcium but growth hormone appears to activate a
voltage-dependent L-type Ca2+
channel in the plasma membrane and the response is not dependent on
JAK2 (54). The Ca2+ response to prolactin is of the same
magnitude as that of erythropoietin but is dependent on mobilization
from intracellular stores as well as external calcium entry (62). The
specific transducers involved in each of these cascades need to be
determined so that shared and receptor-specific pathways can be identified.
The role of intracellular calcium in regulation of cell proliferation
and differentiation is becoming better defined. Calcium has been linked
to expression of proto-oncogenes (63), transcription factor
phosphorylation, and the appearance of a nuclear
Ca2+,Mg2+-dependent endonuclease
capable of generating single strand breaks in chromosomal DNA (64). In
the murine erythroleukemia cell line ELM-1, the
Ca2+/calmodulin-dependent
serine/threonine-specific phosphatase calcineurin (65) mediated
Ca2+-induced down-regulation of c-Myb expression and an
increase in hemoglobin synthesis. Calcium is also involved in
inhibition of DNA binding of basic helix-loop-helix transcription
factors (66) and in the differential activation of NF- We thank Carol Stine for assistance in
experiments with transfected Ba/F3 cells. We are very appreciative of
Tina Eberly for careful preparation of the manuscript.
*
This work was supported by National Institutes of Health
Grants DK 46778 (to B. A. M.), M01 RR10732 (a General Clinical
Research Center grant), F32 DK 09790 (to M-Y. Z.), DK 50693 (to
B. G. N.), F32 DK 09465 (to M. Y.), GM 48991 (to L. I. R.), HL
58672 (to J. Y. C.); Medical Research Council of Canada Grant
MT-13612 (to D. L. B.); and a University of Toronto Connaught New
Staff grant (to D. L. B.). This work received support from the Four
Diamonds Fund.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Recipient of an American Cancer Society Faculty Award. To whom
correspondence should be addressed: Dept. of Pediatrics, MC-H085, The
Milton S. Hershey Medical Center, P. O. Box 850, Hershey, PA 17033-0850. Tel.: 717-531-6012; Fax: 717-531-4789; E-mail: bmiller2@psghs.edu.
The abbreviations used are:
Epo, erythropoietin;
Epo-R, Epo receptor;
mEpoR, murine Epo receptor;
CHO, Chinese hamster
ovary;
CMV, cytomegalovirus;
GFP, green fluorescent protein;
wt, wild-type;
SH2, Src homology 2;
PLC, phospholipase C.
Pediatrics,
|| Medicine, and ¶¶ Cellular and Molecular
Physiology, The Pennsylvania State University College of Medicine,
Milton S. Hershey Medical Center, Hershey, Pennsylvania 17033, the
¶ Division of Cellular and Molecular Biology,
Department of Laboratory Medicine and
Pathobiology,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1
(32), and c-Cbl (33, 34). It is not known whether these transducers are
recruited directly to the Epo-R or bind indirectly via other adaptor proteins.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
221 construct was subcloned from pXM into pcDNA3 (48). Epo-R
tyrosine mutants were generated via overlap extension polymerase chain
reaction. These included a series of single tyrosine mutants in which
phenylalanine was substituted for different tyrosine residues in the
Epo receptor (see Fig. 3) and a series of add back mutants to an Epo
receptor devoid of tyrosine residues. Oligonucleotide primers were
selected that produced either a phenylalanine at amino acid position
443, 460, or 464, or a tyrosine at amino acid position 443, 460, or
464. Polymerase chain reaction was performed using either pBSK-Epo-R or
pBSK-Epo-R F8 (all eight cytoplasmic tyrosines converted to
phenylalanine) to generate a SphI-EcoRI fragment
in pCR-Script. The fidelity of all constructs was confirmed by
sequencing both strands of the 440-base pair fragment. Each SphI-EcoRI fragment was subcloned into
SphI-EcoRI-digested pBSK-Epo-R. The Epo-R
cDNA was subcloned into pCDNA3 or pTracer-CMV using KpnI and EcoRI sites in the pTracer vectors.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (30K):
[in a new window]
Fig. 1.
Detection of GFP and rhod-2 in five CHO cells
transfected with the pTracer-CMV vector. A, white light
image of CHO cells. B, only one of these five CHO cells
successfully expressed GFP (excitation, 380 nm; emission, 510 nm).
C, rhod-2 fluorescence of the same CHO cells (excitation,
540 nm; emission, 590 nm).
Pertussis toxin inhibits the response of transfected CHO cells to Epo
Nifedipine blocks the Epo-induced calcium increase of transfected CHO
cells
221 (
8 tyrosines),
99 Y343F
(
8 tyrosines),
99 (
7 tyrosines),
69 (
6 tyrosines), and
43
(
4 tyrosines) all displayed no calcium influx in response to
erythropoietin stimulation (Table III). The Epo-induced increase in
[Ca]i in mEpo-R
14 (
1 tyrosine) transfected cells was
similar to the wild-type mEpo-R. These results suggested that tyrosines
at position 443, 460, and/or 464 are necessary for Epo-induced calcium
influx.
Transfection of CHO cells with mEpo-R deletion mutants

View larger version (19K):
[in a new window]
Fig. 2.
Schematic representation of wt and deletion
mutants of the mEpo-R. The full-length 483 amino acid wt receptor
possesses 236 amino acids in the cytoplasm. The deletion mutants are
designated based on the number of amino acids deleted from their
cytoplasmic tail. Single-letter amino acid codes used.

View larger version (26K):
[in a new window]
Fig. 3.
Schematic representation of wt mEpo-R
receptor and tyrosine substitution mutants. F8 has all eight
cytoplasmic tyrosines converted to phenylalanine. The Y7 receptor
has phenylalanine substituted for single tyrosines at position 443, 460, or 464. Single-letter amino acid codes used.
Response to Epo of CHO cells transfected with single tyrosine
substitution mutants or add back mutants of mEpo-R

View larger version (28K):
[in a new window]
Fig. 4.
A, Western blot of CHO cells transfected
with mutant mEpo-R. CHO cells were transfected with wt mEpo-R, mEpo-R
F8, mEpo-R-14, or single tyrosine substitution or add back mutants. 30 µg of protein was loaded on each lane. Detection was performed with
ECL. 443F, Phe-443; Y443, Tyr-443. B,
Western blot of Ba/F3 cells transfected with mutant Epo-R. Ba/F3 cells
were transfected with wt mEpo-R and single tyrosine substitution
mutants or add back mutants. One hundred µg of lysate from each cell
line was loaded in each lane.
43 showed no Epo-induced
[Ca]i increase, whereas cells transfected with mEpo-R
14
displayed a significant calcium rise. Furthermore, no increase in
[Ca]i was observed in Ba/F3 cells transfected with mEpo-R Y7
Phe-460, but the calcium response to Epo was specifically restored in
an add back mutant to the F8 mEpo-R in which tyrosine was added back at
position 460 (Fig. 5). All cell lines tested activated the tyrosine
phosphorylation of JAK2, confirming that the Epo-R constructs were
expressed on the cell surface (Fig. 6). This is expected because all
constructs have an intact Box 1/Box 2 region. These data demonstrate
that the mEpo-R Y460F is functional in activating JAK2 but unable to
transmit the calcium signal.

View larger version (16K):
[in a new window]
Fig. 5.
Calcium response of Ba/F3 cells transfected
with mEpo-R. Ba/F3 cells stably transfected with wt or mutant
mEpo-R were deprived of growth factor and then stimulated with 2 units/ml recombinant Epo. Fluorescence intensity ratios
(F350/F380) of Fura-2-loaded cells were obtained with DVI
before Epo stimulation and 1, 5, 10, 15, and 20 min after Epo
stimulation. Results are expressed as the mean ± S.E. of
F350/F380 at
peak/baseline × 100%. The number of single cells studied after
transfection with different mEpo-R constructs was as follows: no
vector, 4; mEpo-R wt, 29; mEpo-R
43, 9; mEpo-R
14, 8; mEpo-R Y7
Phe-460, 16; mEpo-R Y7 Phe-464, 12; mEpo-R F7 Tyr-460, 15; and mEpo-R
F7 Tyr-464, 10. *, significant increase in
F350/F380 above that measured in nontransfected
Ba/F3 cells (p < 0.05).

View larger version (35K):
[in a new window]
Fig. 6.
Epo activates JAK2 in Epo-R constructs with
Tyr-460 mutations. Ba/F3 cells expressing Epo-R, Epo-R Y7 Phe-460,
Epo-R F7 Tyr-460, and Epo-R F8 were depleted of cytokine for 4 h
and then stimulated in the presence or absence of IL-3 or Epo. Lysates
were prepared and immunoprecipitation with a peptide-specific JAK2
antibody performed. Tyrosine phosphorylation of JAK2 was assessed by
immunoblotting with a monoclonal anti-phosphotyrosine antibody
(lanes 1-15). The membrane was stripped and reprobed with a
peptide-specific JAK2 antibody. Whole cell lysates from stimulated
Ba/F3-Epo-R cells were run in lanes 16-18.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
2 (55).
Ras activation is required for insulin-like growth factor II receptor
and Gi
2 coupling, which regulates the IGF-II calcium signaling
pathway in 3T3 cells (55). Because the same pertussis toxin-sensitive
protein (Gi
2) has been shown to be involved in
erythropoietin-mediated calcium channel opening on erythroid precursors
(46, 51), Ras may be involved in the erythropoietin-modulated pathway
and activated by interaction of one of its transducers with the
receptor at Tyr-460. Another transducer that may interact at this site
is the Crk family of adaptor proteins, including CrkI, CrkII, and CrkL
(34). The CrkI proteins, through SH3-dependent
interactions, associate with C3G, a guanine nucleotide release factor
that displays specificity for the activation of the Ras related gene
Rap1. Indeed, Rap1 activation has been shown to be associated with
calcium signaling in platelets and neutrophils (56, 57).
1 (PLC-
1) in
UT-7/Epo cells, resulting in an increase in intracellular calcium (32).
In rat glomerular mesangial cells, erythropoietin promotes the
interaction of phospholipase C-
1 with the erythropoietin receptor as
well as stimulation of a Ca2+-activated,
Ca2+-permeable channel that is dependent on tyrosine
phosphorylation and activation of PLC-
1 (58). Many of the
characteristics of the Epo-mediated rise in intracellular calcium in
normal erythroid and mesangial cells are similar, including the
magnitude of the rise in intracellular calcium, the 20 min peak of
intracellular Ca2+ response, the dependence on tyrosine
phosphorylation, and the regulation of voltage-independent
Ca2+ channel activity (58). However, the PLC-
1 cascade
results in a biphasic rise in intracellular Ca2+ with an
initial increase from inositol 1,4,5-trisphosphate-sensitive intracellular Ca2+ stores followed by influx of
extracellular Ca2+ (58). In previous work, we failed to
measure an increase in inositol 1,4,5-trisphosphate in response to
erythropoietin stimulation of normal erythroid cells (44). In addition,
in transfected CHO and Ba/F3 cells, as in BFU-E-derived erythroblasts,
no increase in calcium in the first minute after stimulation was
observed, as would have been expected with PLC-
1 activation.
Although these data make it less likely that inositol phosphate
hydrolysis is involved in regulating Epo-mediated calcium influx in
erythroblasts, this pathway needs to be explored further.
2, resulting in the blockade of calcium influx.
Although no reports have implicated PLC-
2 in Epo-mediated signaling,
SHIP is a target of Epo-dependent tyrosine phosphorylation
(61). Gene targeting experiments reveal that SHIP knockout mice have
decreased CFU-E in 4- and 8-week-old animals (60). SHIP may regulate
several different signal transduction cascades, including activation of
Erk, PKB/Akt and/or calcium entry. This matter will be resolved by an
analysis of EPO-dependent signaling in primary cells
isolated from the SHIP nullizygous mice.
B factors
(67). Both of these families of transcription factors are involved in
regulation of erythropoiesis (68-71). Here, we have demonstrated the
tyrosine site on the erythropoietin receptor required for activation of the signaling cascade that leads to calcium channel activation. Our
next goals will be identification of the transducers that bind to that
site and their subsequent targets and determination of the specific
nuclear events that are modulated by the nuclear/cytoplasmic calcium
gradient (43) that results.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES

D.L.B. was supported by a Special Fellow Award from the
Leukemia Society of America.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Klingmuller, U.
(1997)
Eur. J. Biochem.
249,
637-647[Medline]
[Order article via Infotrieve]
2.
Ihle, G. N.,
Witthuhn, B. A.,
Quelle, F. W.,
Yamamoto, K.,
and Silvennoinen, O.
(1995)
Annu. Rev. Immunol.
13,
369-398[CrossRef][Medline]
[Order article via Infotrieve]
3.
Ihle, J. N.
(1995)
Nature
377,
591-594[CrossRef][Medline]
[Order article via Infotrieve]
4.
Noguchi, C. T.,
Bae, K. S.,
Chin, K.,
Wada, Y.,
Schechter, A. N.,
and Hankins, W. D.
(1991)
Blood
78,
2548-2556 5.
Maouche, L.,
Tournamille, C.,
Hattab, C.,
Boffa, G.,
Cartron, J.-P.,
and Chretien, S.
(1991)
Blood
78,
2557-2563 6.
D'Andrea, A. D.,
Lodish, H. F.,
and Wong, G. G.
(1989)
Cell
57,
277-285[CrossRef][Medline]
[Order article via Infotrieve]
7.
Middleton, S. A.,
Johnson, D. L.,
Jin, R.,
McMahon, F. J.,
Collins, A.,
Tullai, J.,
Gruninger, R. H.,
Jolliffe, L. K.,
and Mulcahy, L. S.
(1996)
J. Biol. Chem.
271,
14045-14054 8.
Hilton, D. J.,
Watowich, S. S.,
Katz, L.,
and Lodish, H. F.
(1996)
J. Biol. Chem.
271,
4699-4708 9.
Watowich, S. S.,
Hilton, D. J.,
and Lodish, H. F.
(1994)
Mol. Cell. Biol.
14,
3535-3549 10.
Miura, O.,
and Ihle, J. N.
(1993)
Arch. Biochem. Biophys.
306,
200-208[CrossRef][Medline]
[Order article via Infotrieve]
11.
Witthuhn, B.,
Quelle, F. W.,
Silvennoinen, O.,
Yi, T.,
Tang, B.,
Miura, O.,
and Ihle, J. N.
(1993)
Cell
74,
227-236[CrossRef][Medline]
[Order article via Infotrieve]
12.
Miura, O.,
Nakamura, N.,
Quelle, F. W.,
Witthuhn, B. A.,
Ihle, J. N.,
and Aoki, N.
(1994)
Blood
84,
1501-1507 13.
Drachman, J. G.,
Griffin, J. D.,
and Kaushansky, K.
(1995)
J. Biol. Chem.
270,
4979-4982 14.
Damen, J.,
and Krystal, G.
(1996)
Exp. Hematol.
24,
1455-1459[Medline]
[Order article via Infotrieve]
15.
Chin, H.,
Nakamura, N.,
Kamiyama, R.,
Miyasaka, N.,
Ihle, J. N.,
and Miura, O.
(1996)
Blood
88,
4415-4425 16.
Fujitani, Y.,
Hibi, M.,
Fukada, Y.,
Takahashi-Tezuka, M.,
Yoshida, H.,
Yamaguchi, T.,
Sugiyama, K.,
Yamanaka, Y.,
Nakajima, K.,
and Hirano, T.
(1997)
Oncogene
14,
751-761[CrossRef][Medline]
[Order article via Infotrieve]
17.
Wakao, H.,
Harada, N.,
Kitamura, T.,
Mui, A. L.-F.,
and Miyajima, A.
(1995)
EMBO J.
14,
2527-2535[Medline]
[Order article via Infotrieve]
18.
Klingmuller, U.,
Bergelson, S.,
Hsiao, J. G.,
and Lodish, H. F.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
8324-8328 19.
Damen, J. E.,
Wakao, H.,
Miyajima, A.,
Krosl, J.,
Humphries, R. K.,
Cutler, R. L.,
and Krystal, G.
(1995)
EMBO J.
14,
5557-5568[Medline]
[Order article via Infotrieve]
20.
Gobert, S.,
Chretien, S.,
Gouilleux, F.,
Muller, O.,
Pallard, C.,
Dusanter-Fourt, I.,
Groner, B.,
Lacombe, C.,
Gisselbrecht, S.,
and Mayeux, P.
(1996)
EMBO J.
15,
2434-2441[Medline]
[Order article via Infotrieve]
21.
Tauchi, T.,
Feng, G.-S.,
Shen, R.,
Hoatlin, M.,
Bagby, G. C., Jr.,
Kabat, D.,
Lu, L.,
and Broxmeyer, H. E.
(1995)
J. Biol. Chem.
270,
5631-5635 22.
Tauchi, T.,
Damen, J. E.,
Toyama, K.,
Feng, G.-S.,
Broxmeyer, H. E.,
and Krystal, G.
(1996)
Blood
87,
4495-4501 23.
Klingmuller, U.,
Lorenz, U.,
Cantley, L. C.,
Neel, B. G.,
and Lodish, H. F.
(1995)
Cell
80,
729-738[CrossRef][Medline]
[Order article via Infotrieve]
24.
Yi, T.,
Zhang, J.,
Miura, O.,
and Ihle, J. N.
(1995)
Blood
85,
87-95 25.
Damen, J. E.,
Cutler, R. L.,
Jiao, H.,
Yi, T.,
and Krystal, G.
(1995)
J. Biol. Chem.
270,
23402-23408 26.
He, T.-C.,
Zhuang, H.,
Jiang, N.,
Waterfield, M. D.,
and Wojchowski, D. M.
(1993)
Blood
82,
3530-3538 27.
Damen, J. E.,
Mui, A. L.-F.,
Puil, L.,
Pawson, T.,
and Krystal, G.
(1993)
Blood
81,
3204-3210 28.
Torti, M.,
Marti, K. B.,
Altschuler, D.,
Yamamoto, K.,
and Lapetina, E. G.
(1992)
J. Biol. Chem.
267,
8293-8298 29.
Miura, O.,
Miura, Y.,
Nakamura, N.,
Quelle, F. W.,
Witthuhn, B. A.,
Ihle, J. N.,
and Aoki, N.
(1994)
Blood
84,
4135-4141 30.
Hanazono, Y.,
Chiba, S.,
Sasaki, K.,
Mano, H.,
Yazaki, Y.,
and Hirai, H.
(1993)
Blood
81,
3193-3196 31.
Chin, H.,
Arai, A.,
Wakao, H.,
Kamiyama, R.,
Miyasaka, N.,
and Miura, O.
(1998)
Blood
91,
3734-3745 32.
Ren, H.-Y.,
Komatsu, N.,
Shimizu, R.,
Okada, K.,
and Miura, Y.
(1994)
J. Biol. Chem.
269,
19633-19638 33.
Odai, H.,
Sasaki, K.,
Iwamatsu, A.,
Hanazono, Y.,
Tanaka, T.,
Mitani, K.,
Yazaki, Y.,
and Hirai, H.
(1995)
J. Biol. Chem.
270,
10800-10805 34.
Barber, D. L.,
Mason, J. M.,
Fukazawa, T.,
Reedquist, K. A.,
Druker, B. I.,
Band, H.,
and D'Andrea, A. D.
(1997)
Blood
89,
3166-3174 35.
Miller, B. A.,
Scaduto, R. C., Jr.,
Tillotson, D. L.,
Botti, J. J.,
and Cheung, J. Y.
(1988)
J. Clin. Invest.
82,
309-315
36.
Miller, B. A.,
Cheung, J. Y.,
Tillotson, D. L.,
Hope, S. M.,
and Scaduto, R. C., Jr.
(1989)
Blood
73,
1188-1194 37.
Mladenovic, J.,
and Kay, N. E.
(1988)
J. Lab. Clin. Med.
112,
23-27[Medline]
[Order article via Infotrieve]
38.
Misiti, J.,
and Spivak, J. L.
(1979)
J. Clin. Invest.
64,
1573-1579
39.
Gillo, B.,
Ma, Y.-S.,
and Marks, A. R.
(1993)
Blood
81,
783-792 40.
Hensold, J. O.,
Dubyak, G.,
and Housman, D. E.
(1991)
Blood
77,
1362-1370 41.
Levenson, R.,
Houseman, D.,
and Cantley, L.
(1980)
Proc. Natl. Acad. Sci. U. S. A.
77,
5948-5952 42.
Sawyer, S. T.,
and Krantz, S. B.
(1984)
J. Biol. Chem.
259,
2769-2774 43.
Yelamarty, R. V.,
Miller, B. A.,
Scaduto, R. C., Jr.,
Yu, F. T. S.,
Tillotson, D. L.,
and Cheung, J. Y.
(1990)
J. Clin. Invest.
85,
1799-1809
44.
Cheung, J. Y.,
Elensky, M. B.,
Brauneis, U.,
Scaduto, R. C., Jr.,
Bell, L. L.,
Tillotson, D. L.,
and Miller, B. A.
(1992)
J. Clin. Invest.
90,
1850-1856
45.
Cheung, J. Y.,
Zhang, X.-Q.,
Bokvist, K.,
Tillotson, D. L.,
and Miller, B. A.
(1997)
Blood
89,
92-100 46.
Miller, B. A.,
Bell, L.,
Hansen, C. A.,
Robishaw, J. D.,
Linder, M. E.,
and Cheung, J. Y.
(1996)
J. Clin. Invest.
98,
1728-1736[Medline]
[Order article via Infotrieve]
47.
Miller, B. A.,
Bell, L. L.,
Lynch, C. J.,
and Cheung, J. Y.
(1994)
Cell Calcium
16,
481-490[CrossRef][Medline]
[Order article via Infotrieve]
48.
D'Andrea, A. D.,
Yoshimura, A.,
Youssoufian, H.,
Zon, L. I.,
Koo, J. W.,
and Lodish, H. F.
(1991)
Mol. Cell. Biol.
11,
1980-1987 49.
Mitani, A.,
Takeyasu, S.,
Yanase, H.,
Nakamura, Y.,
and Kataoka, K.
(1994)
J. Neurochem.
62,
626-634[Medline]
[Order article via Infotrieve]
50.
Yoshino, M.,
and Kamiya, H.
(1995)
Brain Res.
695,
179-185[CrossRef][Medline]
[Order article via Infotrieve]
51.
Miller, B. A.,
Foster, K.,
Robishaw, J. D.,
Whitfield, C. F.,
Bell, L.,
and Cheung, J. Y.
(1991)
Blood
77,
486-492 52.
Zhang, M.-Y.,
Harhaj, E. W.,
Bell, L.,
Sun, S.-C.,
and Miller, B. A.
(1998)
Blood
92,
1225-1234 53.
Barber, D. L.,
and D'Andrea, A. D.
(1994)
Mol. Cell. Biol.
14,
6506-6514 54.
Billestrup, N.,
Bouchelouche, P.,
Allevato, G.,
Ilondo, M.,
and Nielsen, H.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
2725-2729 55.
Okamoto, T.,
Asanoi, T.,
Harada, S.,
Ogata, E.,
and Nishimoto, I.
(1991)
J. Biol. Chem.
266,
1085-1091 56.
Franke, B.,
Akkerman, J. W.,
and Bos, J. L.
(1997)
EMBO J.
16,
252-259[CrossRef][Medline]
[Order article via Infotrieve]
57.
M'Rabet, L.,
Coffer, P.,
Zwartkruis, F.,
Franke, B.,
Segal, A. W.,
Koenderman, L.,
and Bos, J. L.
(1998)
Blood
92,
2133-2140 58.
Marrero, M. B.,
Venema, R. C.,
Ma, H.,
Ling, B. N.,
and Eaton, D. C.
(1998)
Kidney International
53,
1259-1268[CrossRef][Medline]
[Order article via Infotrieve]
59.
Huber, M.,
Helgason, C. D.,
Damen, J. E.,
Liu, L.,
Humphries, R. K.,
and Krystal, G.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
11330-11335 60.
Helgason, C. D.,
Damen, J. E.,
Rosten, P.,
Grewal, R.,
Sorensen, P.,
Chappel, S. M.,
Borowski, A.,
Jirik, F.,
Krystal, G.,
and Humphries, R. K.
(1998)
Genes Dev.
12,
1610-1620 61.
Damen, J. E.,
Liu, L.,
Rosten, P.,
Humphries, R. K.,
Jefferson, A. B.,
Majerus, P. W.,
and Krystal, G.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
20,
1689-1693
62.
Vacher, P.,
Tran Van Chuoi, M.,
Paly, J.,
Djiane, J.,
and Dufy, B.
(1994)
Endocrinology
134,
1213-1218[Abstract]
63.
Morgan, J. I.,
and Curran, T.
(1986)
Nature
322,
552-555[CrossRef][Medline]
[Order article via Infotrieve]
64.
McMahon, G.,
Alsina, G. L.,
and Levy, S. B.
(1984)
Proc. Natl. Acad. Sci. U. S. A.
81,
7461-7465 65.
Schaefer, A.,
Magocsi, M.,
Stocker, U.,
Fandrich, A.,
and Marquardt, H.
(1996)
J. Biol. Chem.
271,
13484-13490 66.
Corneliussen, B.,
Holm, M.,
Waltersson, Y.,
Onions, J.,
Hallberg, B.,
Thornell, A.,
and Grundstrom, T.
(1994)
Nature
368,
760-764[CrossRef][Medline]
[Order article via Infotrieve]
67.
Dolmetsch, R. E.,
Lewis, R. S.,
Goodnow, C. C.,
and Healy, J. I.
(1997)
Nature
386,
855-858[CrossRef][Medline]
[Order article via Infotrieve]
68.
Zhang, M.-Y.,
Clawson, G. A.,
Olivieri, N. F.,
Bell, L. L.,
Begley, C. G.,
and Miller, B. A.
(1997)
Blood
90,
2068-2074 69.
Shivdasani, R. A.,
Mayer, E. L.,
and Orkin, S. H.
(1995)
Nature
373,
432-434[CrossRef][Medline]
[Order article via Infotrieve]
70.
Condorelli, G.,
Vitelli, L.,
Valtieri, M.,
Marta, I.,
Montesoro, E.,
Lulli, V.,
Baer, R.,
and Peschle, C.
(1995)
Blood
86,
164-175 71.
Zhang, M.-Y.,
Sun, S.-C.,
Bell, L.,
and Miller, B. A.
(1998)
Blood
91,
4136-4144
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
This article has been cited by other articles:
![]() |
Q. Tong, I. Hirschler-Laszkiewicz, W. Zhang, K. Conrad, D. W. Neagley, D. L. Barber, J. Y. Cheung, and B. A. Miller TRPC3 Is the Erythropoietin-regulated Calcium Channel in Human Erythroid Cells J. Biol. Chem., April 18, 2008; 283(16): 10385 - 10395. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Ravid, I. Shams, N. Ben Califa, E. Nevo, A. Avivi, and D. Neumann An extracellular region of the erythropoietin receptor of the subterranean blind mole rat Spalax enhances receptor maturation PNAS, September 4, 2007; 104(36): 14360 - 14365. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Zhang, Q. Tong, K. Conrad, J. Wozney, J. Y. Cheung, and B. A. Miller Regulation of TRP channel TRPM2 by the tyrosine phosphatase PTPL1 Am J Physiol Cell Physiol, May 1, 2007; 292(5): C1746 - C1758. [Abstract] [Full Text] [PDF] |
||||
![]() |
|